NCT00610740View on ClinicalTrials.gov

CerviPrep for Applying Topical Gemcitabine to the Cervix in Treating Patients With Primary Endometrial, Cervical, or Ovarian Epithelial Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

July 31, 2006

Primary Completion Date

April 30, 2008

Study Completion Date

April 30, 2008

Conditions
Cervical CancerEndometrial CancerOvarian Cancer
Interventions
DRUG

topical gemcitabine hydrochloride

Gemcitabine 100 mg/m2 will be administered as a single dose, directly to the cervix via the CerviPrep™ device.

PROCEDURE

therapeutic conventional surgery

hysterectomy

Trial Locations (1)

55455

University of Minnesota Cancer Center, Minneapolis

All Listed Sponsors
lead

Masonic Cancer Center, University of Minnesota

OTHER

NCT00610740 - CerviPrep for Applying Topical Gemcitabine to the Cervix in Treating Patients With Primary Endometrial, Cervical, or Ovarian Epithelial Cancer | Biotech Hunter | Biotech Hunter